Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com -- Instil Bio Inc (NASDAQ:TIL) stock jumped 5.5% in premarket trading following preliminary data from a Phase 2 study of its cancer therapy in China.
The clinical-stage cell therapy company reported that ImmuneOnco Biopharmaceuticals announced positive early results for IMM2510/AXN-2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC). The study showed partial responses in 62% of efficacy evaluable patients, with particularly strong results in squamous NSCLC patients (80% response rate) compared to non-squamous NSCLC patients (46%).
The therapy demonstrated a favorable safety profile with no dose-limiting toxicities observed in the 33 safety evaluable patients. There were no treatment-related adverse events leading to dose reduction or death, and only one case led to drug discontinuation. The most common serious side effects were hematologic, while adverse events typically associated with VEGF inhibition were uncommon and generally low-grade.
Professor Caicun Zhou, lead investigator on the study, noted that the therapy "has demonstrated early but compelling activity in front-line NSCLC patients," adding that the PD-(L)1xVEGF bispecific class has potential to become the new standard of care for front-line NSCLC.
Instil Bio CEO Bronson Crouch expressed satisfaction with the preliminary results, suggesting they indicate "potential for best-in-class efficacy in the promising PD-(L)1xVEGF bispecific antibody class." The company plans to initiate a US phase 1 clinical trial before the end of this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.